Expression levels of Marek's disease virus (MDV) glycoprotein C (gC) are significantly reduced after serial virus passage in cell culture. Reduced gC expression coincides with enhanced MDV growth in vitro and attenuation. To analyze this phenomenon in detail, a full-length infectious MDV clone was modified by Redbased and shuttle mutagenesis in Escherichia coli. Besides a gC-negative deletion mutant harboring a kanamycin resistance gene, a markerless mutant with the U L 44 gene deleted was constructed. On the basis of this deletion mutant, the original or a modified U L 44 gene with a mutated start codon (AUG3ACG) was reinserted into the authentic locus. Similarly, mutants expressing authentic gC or the start codon mutation under the control of a strong constitutive promoter were generated. In vitro studies demonstrated that gC deletion mutants induced twofold-larger plaques than the parental virus did, whereas constitutive overexpression of the glycoprotein resulted in a more than twofold reduction in plaque size. In addition, plaque sizes of the gC deletion mutant were reduced when virus was grown using supernatants from cells infected with parental virus, but supernatants obtained from cells infected with the gC deletion mutant had no measurable effect on plaque size. The results indicated that (i) expression of MDV gC, albeit at low levels in a highly passaged virus, had a significant negative impact on the cell-to-cell spread capabilities of the virus, which was alleviated in its absence and exacerbated by its overexpression, and that (ii) this activity was mediated by the secreted form of MDV gC.Marek's disease virus (MDV), also referred to as gallid herpesvirus 2, is a member of the family Herpesviridae. Within this large virus family it is classified among the Alphaherpesvirinae and is the prototype member of the genus Mardivirus ("Marek's disease-like viruses") (6,34,68). MDV is the causative agent of Marek's disease (MD) in chickens (13), whereas its close relatives and other members of the genus, gallid herpesvirus 3 and herpesvirus of turkeys (HVT; meleagrid herpesvirus, MeHV-1), are completely apathogenic and have been used as MD vaccines since the early 1970s (7,10,52,60). Following the first description of MD in 1907 by Jozef Marek (42), the clinical picture has changed from a polyneuritis associated with general wasting to one that is characterized by visceral lymphomas, transient paralysis, and early mortality within 2 weeks of infection. The virulence of MDV field isolates has increased over the years from mild (m), virulent (v), very virulent (vv), to very virulent plus (vvϩ) strains. While vv strains are able to break HVT vaccination, vvϩ MDV are isolated from flocks vaccinated with a combination of SB-1 (a gallid herpesvirus 3 strain) and HVT (9,74,75).In contrast to other alphaherpesviruses, MDV does not release detectable free enveloped, let alone infectious, virus into the supernatant of cultured cells (8). Similar to varicella-zoster virus (VZV), infectivity in vitro spreads directly onl...